Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

[1]  R. DeRubeis,et al.  Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.

[2]  S. Buyske,et al.  The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[3]  K. Sethi,et al.  A controlled trial of antidepressants in patients with Parkinson’s disease and depression , 2009, Current neurology and neuroscience reports.

[4]  P. Blier,et al.  Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain , 2009, Neuropsychopharmacology.

[5]  K. Marder,et al.  Clinical correlates of depressive symptoms in familial Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[6]  O. Kano,et al.  Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease , 2008, Neuropsychiatric disease and treatment.

[7]  L. Defebvre,et al.  Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[8]  D. Aarsland,et al.  A systematic review of prevalence studies of depression in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[9]  C. Aiken.  Pramipexole in psychiatry: a systematic review of the literature. , 2007, The Journal of clinical psychiatry.

[10]  M. Stern,et al.  Effect of age on geriatric depression scale performance in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[11]  William W. McDonald,et al.  Depression rating scales in Parkinson's disease: Critique and recommendations , 2007, Movement disorders : official journal of the Movement Disorder Society.

[12]  C. Nemeroff,et al.  The role of dopamine in the pathophysiology of depression. , 2007, Archives of general psychiatry.

[13]  Anette Schrag,et al.  Quality of life and depression in Parkinson's disease , 2006, Journal of the Neurological Sciences.

[14]  A. Stiggelbout,et al.  Reliability and validity of the Beck depression inventory in patients with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[15]  R. Marconi,et al.  Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease , 2006, Journal of Neurology.

[16]  Daniel Weintraub,et al.  Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[17]  D. Aarsland,et al.  A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[18]  I. Katz,et al.  Antidepressant studies in Parkinson's disease: A review and meta‐analysis , 2005, Movement disorders : official journal of the Movement Disorder Society.

[19]  Nora Turjanski,et al.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.

[20]  Werner Poewe,et al.  Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. Velíšková,et al.  Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study , 2003, European journal of neurology.

[22]  F. Verhey,et al.  The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[23]  R. Fitzpatrick,et al.  The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. , 1997, Age and ageing.

[24]  M. Hamilton,et al.  A Scale for the Assessment of Hedonic Tone the Snaith–Hamilton Pleasure Scale , 1995, British Journal of Psychiatry.

[25]  P. Willner,et al.  Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole , 1994, Psychopharmacology.

[26]  D. Zelterman.  Statistical Models for Causal Analysis , 1994 .

[27]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[28]  J. Cummings,et al.  Depression and Parkinson's disease: a review. , 1992, The American journal of psychiatry.

[29]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[30]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[31]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[32]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[33]  Guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease , 2012 .

[34]  S. Papapetropoulos,et al.  The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale , 2010 .

[35]  P. Barone,et al.  The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. , 2009, Clinical therapeutics.

[36]  D. Kajdasz,et al.  The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. , 2008, Primary care companion to the Journal of clinical psychiatry.

[37]  G. Skuza,et al.  Antidepressant effects of pramipexole, a novel dopamine receptor agonist , 2005, Journal of Neural Transmission.

[38]  Clarke Ce,et al.  Therapies for depression in Parkinson's disease. , 2003, The Cochrane database of systematic reviews.

[39]  Dwight L. Evans,et al.  Comparison of pramipexole, fluoxetine, and placebo in patients with major depression , 2000, Depression and anxiety.

[40]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[41]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[42]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[43]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[44]  T. L. Brink,et al.  Clinical Gerontology: A Guide to Assessment and Intervention , 1986 .